What the company does
Samsung Biologics is a contract manufacturer of biologic medicines, meaning it produces drugs on behalf of pharmaceutical and biotech companies rather than marketing its own branded therapies.
It runs large-scale facilities that make antibody and other protein-based treatments under contract, and it also offers drug-development support services. Global drugmakers use its capacity to scale up production. The company is part of South Korea's Samsung group.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$3.3B
▲ +0.2% YoY
Operating profit · FY2025
US$1.5B
▲ +56.8% YoY
Net income · FY2025
US$1.3B
▲ +64.7% YoY
Revenue
- FY2023US$2.7B
- FY2024US$3.3B
- FY2025US$3.3B
Operating profit
- FY2023US$807M
- FY2024US$956.6M
- FY2025US$1.5B
Net income
- FY2023US$621.5M
- FY2024US$785M
- FY2025US$1.3B
Key ratios (FY2025)
ROE
23.9%
Debt/Eq
48.4%
Op. margin
45.4%
Net margin
39.2%
Rev. YoY
▲ +0.2%
Why it matters · Context, not a recommendation
It belongs to the Samsung group and is one of several Samsung affiliates active in healthcare and biotechnology.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?